chevron_leftBack
As of 13 June 2026, NeOnc Technologies Holdings, Inc. has a market cap of $107.12M USD, ranking #25036 globally and #3868 in the United States.
It ranks #2240 in the Healthcare sector, and #429 in the Biotechnology industry.
Key Stats
Market Cap
$107.12MUSD
Enterprise Value
$112.63MUSD
Revenue (TTM)
$39.99KUSD
Net Income (TTM)
-$62.15MUSD
PS Ratio
2660.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Amir Heshmatpour
open_in_new
Employees
5
Founded
2008
Website
neonc.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.2% | -22% | -45% | -59% | -54% | -33% |
News
Loading...
NTHI Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NTHI
NeOnc Technologies Holdings Inc
ISIN: US64051A1016
Shares Out.:
Shares Outstanding:
26.013M1
Shares Float:
3.841M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.30 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
170K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
149K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
26K%
|
-
|
|
NYSE: IQV
|
$26.3B
24K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
23K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
17K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
45K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
42K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
39K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
39K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
26K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
24K%
|
-
|
chevron_leftBack